Clinical Trial

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
Protocol Amendment History 1 change
notable Trial sites expanded: 3 -> 10 locations 2026-04-01
Trial Details
NCT Number NCT07277413
Lead Sponsor IDEAYA Biosciences
Conditions NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma +5 more
Enrollment 260 participants
Start Date 2026-03-04
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-05